Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Polyclonal PIAS3 Primary Antibody for IHC (p), WB - ABIN1882115
Nojiri, Joh, Miura, Sakata, Nomura, Nakao, Sobue, Ohara, Asai, Ito: ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. in Biochemical and biophysical research communications 2004
Show all 7 Pubmed References
Human Polyclonal PIAS3 Primary Antibody for IHC (p), WB - ABIN1882116
Long, Wang, Matsuura, He, Liu: Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). in Proceedings of the National Academy of Sciences of the United States of America 2004
Show all 7 Pubmed References
Suppressed Th17 levels correlated with upregulated expression of negative regulatory genes, PIAS3, SHP2, and SOCS3 in CD4 T cells during acute SIV infection.
Results show that PIAS3 levels are reduced in a mouse model of atherosclerotic lesions and that its expression decreases in conjunction with increases in interleukin-6 (show IL6 Antibodies) expression and disease severity. These findings provide evidence that results indicate that PIAS3 is a critical repressor of atherosclerosis progression.
Data indicate that PIAS3 (protein inhibitor of activated STAT3) interaction modulates EKLF (erythroid Kruppel-like factor (show KLF1 Antibodies)) activity in a promoter-dependent and SUMO-independent manner.
PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 (show STAT3 Antibodies) activation.
These data indicate that tachypacing decreased ATBF1 (show ZFHX3 Antibodies), leading to enhanced STAT3 (show STAT3 Antibodies) DNA-binding activity due to the reduced formation of a binary complex of ATBF1 (show ZFHX3 Antibodies) and PIAS3.
MRL/lpr (show FAS Antibodies) mice have significantly increased expressions of STAT3 (show STAT3 Antibodies) mRNA and protein and decreased expression of mRNA PIAS3 in the kidneys compared with BALB/C mice.
L97A, R99N and R99Q mutations of the PINIT domain (PIAS3(85-272) ) were found to abrogate binding to STAT3 (show STAT3 Antibodies), suggesting that these residues were part of a potential binding surface.
Our results indicate that Pias3-dependent SUMOylation of photoreceptor-specific transcription factors is a common mechanism that controls both rod and cone photoreceptor subtype specification, regulating distinct molecular targets in the two cell types
there is an interaction between Zimp7 (show ZMIZ2 Antibodies) and PIAS (show PIAS1 Antibodies) proteins with higher preference for PIAS3, in androgen receptor (show AR Antibodies)-mediated transcription
results indicate a potential role of PIAS3 as transcriptional modulator of TIF2 (show NCOA2 Antibodies)-mediated signalling
role in inducing SUMO-1 (show SUMO1 Antibodies) modification and transcriptional repression of IRF-1 (show IRF1 Antibodies)
PAI-1 (show SERPINE1 Antibodies) interacted with PIAS3 to regulate Stat3 (show STAT3 Antibodies)-dependent gene expression and miR (show MLXIP Antibodies)-34a was transcriptionally suppressed by Stat3 (show STAT3 Antibodies) to form a positive regulatory loop through Stat3 (show STAT3 Antibodies) signaling in non-small cell lung cancer cells.
Levels of PIAS3 are significantly lower, in contrast with phosphorylation of STAT3 (show STAT3 Antibodies), in women with endometriosis compared to women without endometriosis.
TRIM8 (show TRIM8 Antibodies) activates STAT3 (show STAT3 Antibodies) by suppressing the expression of PIAS3, an inhibitor of STAT3 (show STAT3 Antibodies), most likely through E3-mediated ubiquitination and proteasomal degradation.
Low PIAS3 expression is associated with breast cancer organoid invasiveness.
SHP2 (show PTPN11 Antibodies), SOCS3 (show SOCS3 Antibodies) and PIAS3 levels are reduced in medulloblastomas in vivo and in vitro, of which PIAS3 downregulation is more reversely correlated with STAT3 (show STAT3 Antibodies) activation. In resveratrol-suppressed medulloblastoma cells with STAT3 (show STAT3 Antibodies) downregulation and decreased incidence of STAT3 (show STAT3 Antibodies) nuclear translocation, PIAS3 is upregulated, the SHP2 (show PTPN11 Antibodies) level remains unchanged and SOCS3 (show SOCS3 Antibodies) is downregulated.
The results revealed that although the expression levels of SOCS1 (show SOCS1 Antibodies), SOCS3 (show SOCS3 Antibodies) and, in particular, pSHP2, tend to decrease in the four types of astrocytomas, PIAS3 downregulation is more negatively correlated with STAT3 (show STAT3 Antibodies) activation in the stepwise progress of astrocytomas and would indicate an unfavorable outcome.
3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 (show STAT3 Antibodies) signaling through the induction of PIAS3.
PIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to those breast cancer patients receiving hormone therapy.
Taken together, these results suggest that PIAS3 functions as a positive regulator of HIF-1alpha (show HIF1A Antibodies)-mediated transcription by increasing its protein stability.
PIAS3 suppression may be protective against joint destruction in rheumatoid arthritis by regulating synoviocyte migration, invasion, and activation.
This gene encodes a member of the PIAS
protein inhibitor of activated STAT, 3
, E3 SUMO-protein ligase PIAS3-like
, e3 SUMO-protein ligase PIAS3-like
, E3 SUMO-protein ligase PIAS3
, protein inhibitor of activated STAT protein 3
, zinc finger, MIZ-type containing 5
, potassium channel regulatory protein KChAP
, potassium channel-associated protein